The North American Biosimilars Market is the sector of the healthcare industry focused on developing, manufacturing, and commercializing biosimilars, which are complex biological medicines that are scientifically proven to be highly similar to an existing FDA-approved ‘reference’ biologic product. These are not exact copies like generic drugs because biologics are large, intricate molecules produced in living organisms, but biosimilars must demonstrate there are no clinically meaningful differences in terms of safety or effectiveness. The market’s main objective is to increase competition and patient access to costly but essential treatments for chronic and life-threatening conditions like cancer and autoimmune diseases, offering high-quality alternatives once the original product’s patent protection expires.
Download PDF BrochureInquire Before Buying
The North American Biosimilars Market was valued at $XX billion in 2025, will reach $XX billion in 2026, and is projected to hit $XX billion by 2030, growing at a robust compound annual growth rate (CAGR) of XX%.
The global biosimilars market was valued at $32.75 billion in 2024, is projected to reach $35.04 billion in 2025, and is expected to grow at a robust 7.5% Compound Annual Growth Rate (CAGR), hitting $72.29 billion by 2035.
Drivers
The North American biosimilars market is primarily driven by the continuously increasing prevalence of chronic diseases, such as cancer, arthritis, and autoimmune disorders. These conditions require long-term treatment with effective biologic therapies. Since biosimilars offer a highly similar and cost-effective alternative to expensive originator biologics, they are becoming crucial for managing the growing disease burden, improving patient access to necessary treatments, and providing financial relief to strained healthcare systems across the region.
A major growth catalyst is the impending and ongoing patent expiration of numerous blockbuster biologic drugs in the US and Canada. The loss of exclusivity for top-selling reference products, such as Humira and Herceptin, opens up substantial market opportunities for biosimilar entry. This patent cliff is creating a clear path for pharmaceutical companies to develop and commercialize their biosimilar versions, accelerating market competition and subsequently driving down overall drug costs for payers and patients.
The high financial burden imposed by the soaring cost of innovator biologic drugs is strongly pushing market adoption. Biosimilars typically offer a significant discount, often ranging from 44% to 69% lower than the reference product’s price. This competitive pricing acts as a powerful incentive for health systems, insurance providers, and patients to switch to biosimilars, promoting the sustainability of the healthcare budget and ensuring a wider patient base can afford and access life-saving treatments.
Restraints
One significant restraint is the high cost and complexity associated with the development and manufacturing of biosimilars. Bringing a biosimilar to market can cost between $100 million and $300 million, requiring substantial upfront investment in R&D, specialized bioprocessing infrastructure, and technical expertise. The need to establish an independent manufacturing process that reliably matches the quality attributes of the reference product creates high entry barriers for potential manufacturers.
Regulatory hurdles and the lengthy approval process, particularly in the US, represent a substantial restraint. Biosimilars must demonstrate high similarity and no clinically meaningful differences from the reference product, which requires extensive comparative data. The additional burden of achieving the interchangeability designation, which historically mandated switching studies, further complicates and delays market entry, increasing the time-to-market and overall regulatory compliance costs.
Physician skepticism and low patient acceptance due to concerns over efficacy, safety, and the practice of switching remain a significant barrier to widespread adoption. Although studies have shown no reported differences in the clinical profiles of biosimilars, the lack of awareness and trust among clinicians and patients can slow uptake. Overcoming this requires targeted and sustained educational initiatives to reinforce confidence in the safety and effectiveness of biosimilar alternatives.
Opportunities
The substantial sales exposure from biologics losing exclusivity over the next decade presents an immense opportunity. Between 2025 and 2034, approximately 118 biologics with total pre-expiry sales of $234 billion are expected to lose patent protection in the US. This patent cliff provides an unprecedented window for biosimilar developers to target and launch products in high-value therapeutic areas, maximizing market penetration and capturing significant revenue share in the North American market.
Favorable legislative and reimbursement changes, particularly in the US Medicare system, are creating a positive market environment. The Inflation Reduction Act (IRA) and the Medicare Part B add-on payment incentive for biosimilars with an average sales price lower than the originator product are designed to encourage biosimilar utilization. These economic policies provide a clear financial advantage to healthcare providers for prescribing and administering biosimilars, boosting their adoption rates.
Expansion into complex therapeutic fields, such as oncology, autoimmune, and inflammatory disorders, represents a major growth opportunity. Oncology biosimilars, for drugs like rituximab and trastuzumab, are gaining traction due to clear regulatory approval pathways and high demand for affordable cancer treatments. This focus on high-impact disease areas allows biosimilar manufacturers to leverage their advanced capabilities for significant commercial success.
Challenges
A primary challenge involves navigating the complex legal landscape and countering the defensive strategies employed by originator drug companies. Patent disputes and litigation can significantly delay the entry of biosimilars into the North American market, increasing legal costs and discouraging investment. Anti-competitive practices designed to limit biosimilar expansion are an ongoing hurdle that requires continuous regulatory oversight and judicial action to ensure fair market competition.
The technical difficulty in consistently scaling up the complex bioprocessing of biosimilars from laboratory to high-volume commercial production is a persistent challenge. Manufacturers struggle with maintaining quality control while replicating intricate molecular features across large batches. This scaling issue, combined with the limited availability of specialized manufacturing facilities and skilled bioprocessing personnel, presents a barrier to meeting the high market demand efficiently.
The North American market faces the challenge of the “biosimilar void,” where a number of biologics nearing patent expiration, including some with high sales potential, currently lack a biosimilar development pipeline. Factors such as the complexity of the molecule, small patient populations (orphan status), and overall commercial uncertainty limit developer interest. Addressing this void is crucial for fully realizing the potential cost savings for the healthcare system.
Role of AI
Artificial Intelligence is transforming biosimilar research and development by enabling advanced in silico modeling. AI algorithms can analyze complex protein structures, predict stability, and simulate drug-receptor interactions, thereby narrowing down viable biosimilar candidates faster than traditional lab methods. This application significantly reduces the time and cost associated with the early development stages, accelerating the design of highly similar and less immunogenic molecules.
AI plays a critical role in enhancing the manufacturing and quality control processes through ‘smart manufacturing’ systems. Machine learning models use real-time data from bioreactors and purification steps to predict and auto-adjust critical process parameters. This ensures batch-to-batch consistency and high quality, which is vital for biosimilars, ultimately improving manufacturing efficiency, reducing waste, and facilitating the complex scale-up process.
The integration of AI into clinical development streamlines trial design and post-market surveillance. AI can optimize patient selection, predict clinical outcomes, and analyze large volumes of comparative data to demonstrate bioequivalence efficiently. Furthermore, AI-driven pharmacovigilance tools continuously monitor real-world data to rapidly detect any rare adverse events, strengthening regulatory compliance and reinforcing physician and patient confidence in the biosimilar’s long-term safety profile.
Latest Trends
A key trend is the accelerating pace of biosimilar approvals and the increasing importance of the interchangeable designation in the US. With the FDA approving a rising number of biosimilars, and new guidelines easing the path to interchangeability, market competition is intensifying. This designation allows pharmacists to substitute the biosimilar for the reference product without a physician’s intervention, a critical factor driving rapid market uptake and cost savings.
The implementation of mandatory biosimilar switching policies in Canada is a major market trend. Under the Biosimilars Initiative in multiple provinces, patients with public drug coverage must transition from the originator biologic to an approved biosimilar. This national trend provides a stable and attractive market for biosimilar manufacturers, driving adoption rates and ensuring significant cost reductions for provincial healthcare plans.
There is a growing technological trend toward integrating digital health, such as IoT and advanced data analytics, with biosimilar monitoring. Connected devices and AI-powered systems are increasingly used to track real-world evidence, optimize drug delivery, and monitor patient adherence and outcomes. This convergence supports personalized medicine, enhances post-marketing data collection, and reinforces the overall value proposition of biosimilars within the broader healthcare ecosystem.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40